Introduction
Peripheral T-cell lymphoma (PTCL) is a rare haematological malignancy accounting for 3.7% of all lymphomas and 10-15% of all non-Hodgkin lymphomas (NHL) [1, 2] . Peripheral T-cell lymphoma not otherwise specified (PTCL, NOS) is the commonest subtype of PTCL. However, its' prevalence is lower in Asia than in the West [3] . Only 11 cases of T-cell lymphoma, NOS were reported in Sri Lanka in 2010 [4] . However, PTCL, NOS subtype is not mentioned in this report. PTCL, NOS is a highly aggressive lymphoma notorious for chemo-refractoriness and frequent relapses. High-dose chemotherapy with autologous stem cell transplantation is incorporated in to primary therapy for young fit patients but remains ineffective for most and has not been tested in a randomized study [5] . Allogeneic haematopoietic stem cell transplantation (allo-HSCT) may offer a potential cure for these patients though the optimal type and timing of transplantation remain to be defined [6] .
We report a case of relapsed chemo-refractory PTCL, NOS in a young Sri Lankan man who responded to an allo-HSCT performed for the first time in Sri Lanka.
Case report
A 37-year old previously healthy man from Sabaragamuwa province in Sri Lanka presented with a productive cough and progressive loss of appetite and weight over 2 months. Examination showed generalized lymphadenopathy without any skin lesions or hepatosplenomegaly. Following 6 cycles of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy he went in to remission by PET/CT. Within 2 months he relapsed with generalized lymphadenopathy and constitutional symptoms. Relapsed PTCL, NOS was confirmed on a repeat lymph node biopsy. Salvage chemotherapy with gemcitabine, cisplatin and dexamethasone was given without a significant response. PET/CT scan confirmed rapidly progressive disease post 2 cycles of chemotherapy.
HLA typing of siblings revealed a 10/10 match with his younger brother. Matched sibling allo-HSCT was done at Asiri Central hospital, Colombo with reduced intensity conditioning (RIC) using Fludarabine, Melphalan and antithymocyte globulin. RIC was selected anticipating disease eradication and achieving a graft versus lymphoma (GVL) Vol. 63 
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Case report effect. Cyclosporine was given for graft versus host disease (GVHD) prophylaxis. Peripheral blood stem cells from his brother (dose=9×10 6 /kg CD34+ cells) were infused on day 0. It was well tolerated with only grade 2 mucositis. Neutrophil and platelet engraftment was seen on post-transplant day+9 and +10 respectively. Chimerism testing on days+15, +60, +98 revealed >98% donor DNA.
In the absence of graft versus host disease, cyclosporine was discontinued after day+100. PET/CT scan 4 months' post HSCT showed a complete metabolic response. He is not on any medication and remains well 7 months after HSCT.
Discussion
PTCL, NOS is diagnosed when other specific entities of mature T-cell lymphomas have been excluded [7] . It is a highly aggressive disease with a 5-year overall survival of 20-30% and poor response to therapy [7] . Median age of presentation is 60-years. Male predominance. Most present with peripheral lymphadenopathy. Extranodal involvement is common in skin and gastro-intestinal tract. Many, like our patient, present in advanced stages. PTCL, NOS has heterogeneous morphological, immunohistochemistry and molecular features [3] . Reed Sternberg cells are seen in some with Epstein-Bar virus positivity, as in our patient. Cases of PTCL with Epstein-Bar virus positive Reed Sternberg like cells are uncommon [8] . As in our patient, CD20 positivity in PTCL, NOS is also rarely reported and is associated with a more aggressive clinical course [9] .
CHOP is the standard first line treatment for primary disease. Consolidation with auto-HSCT may provide a survival benefit, however limited by early relapses and frequent chemo-refractoriness [3] . Aberrant CD20 expression may need further evaluation for Rituximab use.
Relapsed/refractory cases have several options including combination chemotherapy, autologous or allogeneic HSCT, novel therapies including monoclonal antibodies, immuneconjugates, histone deacetylase inhibitors and anti-folates [3] .
Reported cases of PTCL, NOS treated with allo-HSCT are extremely rare and it's been suggested that outcomes are better if performed early in relapse [3] , as was done in our patient.
Conclusion
This report adds to the literature the role of allo-HSCT in PTCL, NOS and highlights the importance of timely provision of this treatment modality to suitable patients.
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